A nasal spray developed by researchers from Chulalongkorn University which could help reduce the risk of catching Covid-19 will be available for the public to purchase starting on Oct 1.
The spray, which will be sold under the brand name “VAILL CITITRAP Anti-Cov Nasal Spray”, is produced by Hibiocy, a subsidiary of the cosmetics conglomerate Rojukiss International.
Developed by a team of doctors and researchers from Chulalongkorn University’s Faculty of Medicine, the spray is truly a Thai innovation for Thai people, said Rojukiss CEO Worawarn Chaikamnerd.
A newly developed anti-Covid nasal spray is launched and is now available for commercial sale. Apichart Jinakul
The spray is designed to coat the user’s nasal cavities with a layer of hydroxypropyl methylcellulose, which acts as a physical barrier from the virus. It can be applied every six hours, up to three times a day.
More information can be obtained on Line by adding @Covitrap, Facebook as well as from pharmacists at the Government Pharmaceutical Organization’s drugstores and clinics, she said.
Nopporn Chuenklin, director of the Health System Research Institute (HSRI), praised the patented product, calling it an outstanding Thai innovation.